YOU ARE HERE:
Resistance news
page  of 10
 
Headline
Date
  XDR TB emerging despite good adherence, due to sub-optimal treatment and bad infection control
10.02.10
  Even very low levels of pre-existing resistance increase risk of efavirenz failure
10.02.10
  Less resistance with FTC than 3TC when combined with tenofovir
08.02.10
  Adherence: study shows protease inhibitors more forgiving of missed doses, even when treatment out of date
02.02.10
  New resistance becoming rarer as more patients achieve undetectable HIV viral load
05.01.10
  Most NNRTI-experienced patients in southern Africa will benefit from etravirine
18.12.09
  US guidelines now favour treatment at CD4 cell counts between 350 and 500; above 500 not ruled out
01.12.09
  Transmitted drug-resistant HIV stabilising in Europe
21.10.09
  Etravirine, darunavir/ritonavir and raltegravir very effective in highly treatment-experienced patients
19.10.09
  Delays in switching treatment: NRTI resistance can be slower to emerge than expected
08.09.09
  Cheap viral load test is as reliable as standard: Botswana places large order
01.09.09
  Transmission of resistant HIV common in clusters of newly infected individuals
10.06.09
  Starting treatment at lower CD4 cell counts increases risk of HIV drug resistance
02.06.09
  Rate of transmitted drug-resistant HIV stable in France
18.03.09
  Swiss study finds moderate drug resistance; highlights difficulty of interpreting trends in changing treatment populations
16.03.09
  HIV transmission rate in US has declined enormously
16.12.08
  Widespread resistance to antiretrovirals among children in the Central African Republic
03.12.08
  Raltegravir may have role in PEP if exposure involves drug-resistant HIV
20.11.08
  Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
13.11.08
  South African resistance survey confirms that clade C is more likely to develop multi-drug resistance mutation
12.11.08

page  of 10